Zhang Hao-Yang, Huang Han, Pang Li-Jian, Lv Xiao-Dong, Zheng Wei-Dong
Graduate School, Liaoning University of Traditional Chinese Medicine.
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine.
Medicine (Baltimore). 2021 May 7;100(18):e25802. doi: 10.1097/MD.0000000000025802.
Acute exacerbation is a primary cause of repeated hospitalization and death in chronic obstructive pulmonary disease (COPD) patients. Therefore, how to control the symptoms of COPD at stable stage and reduce the number of acute exacerbation is a hot spot of medical research. Acupoint application (AA) is a significant part of external treatment of traditional Chinese medicine (TCM), Previous researches have reported that AA can be applied to the treatment of COPD. Nevertheless, its effectiveness is still inconclusive. This systematic review (SR) and meta-analysis is designed to appraise its effectiveness and safety for the treatment of patients with COPD.
Eight databases will be systematically retrieved from their inceptions to February 2021. Inclusion criteria are randomized control trials of AA combined with routine western medicine interventions in the treatment of COPD at stable stage. The primary outcomes we focus on comprise clinical effective rate, TCM symptom score, quality of life, dyspnea, exercise capacity, lung function, frequency of acute exacerbation, adverse events. The research screening, data extraction, and risk of bias assessment will be conducted by 2 individuals independently, and divergence will be adjudicated by a third senior investigator. The Stata 13.1 software will be used for meta-analysis. The confidence of evidence will be classified adopting grading of recommendations assessment, development and evaluation (GRADE) algorithm and methodological quality of this SR will be assessed using assessment of multiple systematic reviews-2 (AMSTAR-2) tool.
This SR will provide evidence-based medical proof for the treatment of COPD at stable stage by AA combined with conventional western medicine interventions. The findings of this SR will be presented at relevant conferences and submitted for peer-review publication.
The findings of this SR will provide up-todated summary proof for evaluating the effectiveness and safety of AA for COPD.
INPLASY 202140080.
急性加重是慢性阻塞性肺疾病（COPD）患者反复住院和死亡的主要原因。因此，如何在稳定期控制COPD症状并减少急性加重次数是医学研究的热点。穴位贴敷（AA）是中医外治法的重要组成部分，以往研究报道AA可用于COPD的治疗。然而，其有效性仍尚无定论。本系统评价（SR）和荟萃分析旨在评估其治疗COPD患者的有效性和安全性。
将从建库至2021年2月对八个数据库进行系统检索。纳入标准为AA联合西医常规干预治疗稳定期COPD的随机对照试验。我们关注的主要结局包括临床有效率、中医症状评分、生活质量、呼吸困难、运动能力、肺功能、急性加重频率、不良事件。研究筛选、数据提取和偏倚风险评估将由两名研究人员独立进行，分歧将由第三位资深研究人员裁决。将使用Stata 13.1软件进行荟萃分析。采用推荐意见评估、制定与评价（GRADE）算法对证据的可信度进行分级，并使用多重系统评价评估-2（AMSTAR-2）工具评估本SR的方法学质量。
本SR将为AA联合西医常规干预治疗稳定期COPD提供循证医学证据。本SR的研究结果将在相关会议上展示，并提交同行评议发表。
本SR的研究结果将为评估AA治疗COPD的有效性和安全性提供最新的汇总证据。
INPLASY 202140080。
